So it is OK to ignore other significant parts of the pharmaceutical industry for comparisons sake in terms of violations?
For example from https://violationtracker.goodjobsfirst.org/parent-totals
This is where we start to see other multinational pharmaceutical businesses, down to and including Novartis. Not the best in a manner of speaking, but this is a better view point. One way of looking at this could be Novartis has incurred $2B less in fines than the leader of the pack, with half the number of violations as recorded.
Pfizer, where have I heard that name recently...... I did mention Johnson and Johnson a little earlier too. Oooh and looky there, Teva, well at least we did 3 or so better than last time
- Forums
- ASX - By Stock
- MSB
- Ann: Novartis and Mesoblast Remestemcel-L Collaboration
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-297
-
- There are more pages in this discussion • 515 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
97.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.116B |
Open | High | Low | Value | Volume |
98.5¢ | 98.5¢ | 96.5¢ | $1.379M | 1.413M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 86381 | 97.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 38213 | 42 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 88902 | 0.970 |
21 | 175134 | 0.965 |
16 | 241424 | 0.960 |
6 | 82065 | 0.955 |
9 | 473283 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
0.975 | 36762 | 41 |
0.980 | 134233 | 18 |
0.985 | 84585 | 11 |
0.990 | 114193 | 11 |
0.995 | 124537 | 3 |
Last trade - 15.02pm 23/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online